PROPRANOLOL hydrochloride (Inderal), a new beta adrenergic receptor blocking agent, apparently possessing a potency ten to 20 times that of its predecessor, pronetalol,1 yet lacking its tumor producing qualities in mice,2 recently has received clinical trial in the treatment of angina pectoris.
Strivastava and associates3 using propranolol, 20 mg three times daily in a double-blind study of 20 patients exhibiting angina pectoris, found no statistically significant difference in frequency of angina pectoris or nitroglycerin consumption. However, Keelan4 in a similar study of 19 patients but employing larger doses of propranolol, 30 mg three times daily, observed significant reduction in frequency of angina pectoris and in number of nitroglycerin tablets used. Gillam and Prichard,5 utilizing maximum tolerated doses of propranolol, 30 mg to a ceiling of 100 mg four times daily, recorded significant improvement in all 14 patients studied.
The present paper reports the results of